Breaking News

Merck KGaA Secures Exclusive Worldwide Rights to Bavencio

Merck will have rights to develop, manufacture and commercialize Bavencio.

Merck KGaA is regaining exclusive worldwide rights to develop, manufacture, and commercialize anti-programmed death ligand-1 (PD-L1) antibody Bavencio (avelumab) following the termination of its alliance agreement with Pfizer. Effective June 30, 2023, Merck KGaA, through its affiliate Ares Trading S.A., will take full control of the global commercialization of Bavencio. The current profit share will be replaced by a 15% royalty to Pfizer on sales of Bavencio. Merck KGaA and Pfizer will contin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters